Skip to main content
Zentek Ltd. logo

Zentek Ltd. — Investor Relations & Filings

Ticker · ZTEK TSXV Professional, scientific and technical activities
Open in API
Filings indexed 308 across all filing types
Latest filing 2022-09-15 Regulatory Filings
Country CA Canada
Listing TSXV ZTEK

About Zentek Ltd.

https://www.zentek.com/

Zentek Ltd. is an intellectual property development and commercialization company focused on applying advanced nanotechnology and nanomaterials, specifically graphene, to solve complex challenges in health, safety, and the environment. The company specializes in developing and commercializing next-generation healthcare solutions across prevention, detection, and treatment. Zentek utilizes strategic partnerships to advance its patented nanotechnologies. A key commercialized product is ZenGUARD™, an antimicrobial coating that employs a graphene-silver combination to significantly enhance viral and bacterial filtration performance in applications such as surgical masks and air filters.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on HVAC testing results related to Zentek's product. It discusses the completion of Phase 1 testing and ongoing Phase 2 testing, with no financial data or regulatory filing references. The document is short (3672 characters) and serves as a corporate announcement about product development progress rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is an update on company activities, best classified as a general Regulatory Filing (RNS) since it is a miscellaneous corporate announcement not fitting other specific categories.
2022-09-15 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a company update on commercial partnerships and agreements related to its proprietary product ZenGUARD™. It discusses agreements with Ekomed and Trebor, including the termination of the Trebor Agreement due to receivership. There is no financial data, no mention of quarterly or annual results, no regulatory filings or certifications, and no mention of shareholder meetings or votes. The document is a business update or press release about commercial partnerships and operational status, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The closest fitting category is Capital/Financing Update (CAP) since it relates to commercial agreements and partnerships impacting the company's business operations and potential revenue streams. Confidence is high as the content clearly focuses on commercial partnership updates and not on other filing types.
2022-08-06 English
Interim MD&A - English.pdf
Regulatory Filings
2022-08-05 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of Zentek Ltd. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2022. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3540 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2022-08-05 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of Zentek Ltd. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2022. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3659 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2022-08-05 English
Interim financial statements/report – English.pdf
Regulatory Filings
2022-08-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.